929 results about "Murine model" patented technology

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The invention relates to an immune humanized liver cancer patient-sourced xenotransplantation mouse model and a construction method and application thereof, and belongs to the technical field of medical research and biologication.The immune humanized liver cancer PDX model is innovatively constructed by optimizing transplantation of tumor tissues and introducing and screening immune cells, and the model has the advantages of being high in specificity, high in sensitivity and high in reliability. The defects of a traditional PDX model in immune system and immunotherapy evaluation are overcome. The model has tumor characteristics of liver cancer patients and a functional human immune system, has reliable immune response and anti-cancer treatment evaluation capability, and provides scientific and reliable model support for research and screening of novel liver cancer immunotherapy.

The invention belongs to the technical field of biology, and particularly relates to a cryptosporidium parvum infection immunosuppression mouse model and a construction method thereof. Aiming at the problem that the development of cryptosporidiosis drugs and vaccines is seriously limited due to the fact that no model for successfully infecting mice with cryptosporidium parvum exists at present, the invention provides the construction method of the cryptosporidium parvum infection immunosuppression mouse model, which comprises the following steps: firstly, carrying out gavage treatment on the mice for 4-7 days by adopting cyclophosphamide; constructing to obtain an immunosuppressive mouse; feeding PBS (Phosphate Buffer Solution) containing cryptosporidium parvum oocysts through the mouth, and infecting for 7-21 days; and when oocysts are continuously detected from excrement of the mouse and the content of the oocysts is higher than the infection amount, constructing the cryptosporidium parvum infection immunosuppression mouse model. The cryptosporidium parvum infection immunosuppression mouse model is successfully constructed, can be used for subsequent drug and vaccine development tests for cryptosporidium parvum diseases, and has a good application prospect.

The invention relates to the technical field of image recognition, in particular to an adhesion focus positioning method for an endometriosis rat model, which comprises the following steps of: firstly, adjusting a clustering distance according to color difference between saturation connected domains and a position inertial system, and clustering to obtain a connected domain cluster; due to the fact that the connected domain clusters contain the ectopic glands, the clusters need to be screened to obtain the ectopic glands, the gland probability of each connected domain cluster is obtained according to the characteristic that columnar epithelial cells are distributed on the inner walls of the ectopic glands, and the possibility that each connected domain cluster belongs to the ectopic glands is judged; due to the fact that the ectopic glands are distributed in a concentrated mode, the abnormal probability of the connected domain clusters is obtained through the aggregation of the connected domain clusters with the high gland probability, the possibility that the connected domain clusters belong to the abnormal ectopic glands is further judged, and the focus positioning accuracy of the endometriosis rat model is higher.

The invention provides application of a compound for regulating and controlling an METTL3 target spot in preparation of an anti-enterovirus drug, and belongs to the field of biological medicine, the compound is AN-465 / 42162872, and the compound has a relatively strong anti-EV71 effect in both in-vitro and in-vivo infection models. An in-vitro cell experiment, EV71 infected C57BL / 6 suckling mouse model, m6A methylation sequencing and other methods are utilized to research the activity and potential action mechanism of anti-EV71, and the result shows that AN-465 / 42162872 can inhibit duplication of EV71 in a human RD cell strain in a dose-dependent manner under the condition of maintaining relatively good cell activity, so that the application of AN-465 / 42162872 in the preparation of the EV71 drug is developed. The action mechanism is mainly as follows: the methylation level of the 5002 adenine in the 2C region of EV71 nucleic acid is remarkably reduced by regulating the METTL3, so that virus replication is inhibited, and the METTL3 has relatively high anti-EV71 drug utilization value.

The invention relates to application of cembratrienol in preparation of a medicine for preventing and / or treating psoriasis, and belongs to the technical field of biological medicine. The invention provides an application of cembratrienol in preparation of a medicine for preventing / or treating psoriasis. Researches find that cembratrienol can significantly inhibit secretion of inflammatory factors in a psoriasis-like cell model induced by M5; moreover, research finds that cembratrienol can significantly improve the skin lesion condition of an imiquimod-induced psoriasis mouse model, improve the weight loss degree of the psoriasis mouse model, relieve the pruritus condition of the psoriasis mouse model, improve the skin inflammation of the psoriasis mouse model, repair the skin barrier of the psoriasis mouse model, and improve the curative effect of the psoriasis mouse model. The body immune response of the psoriasis mouse model is reduced. Therefore, cembratrienol has a great application prospect in preparation of the medicine for preventing / treating psoriasis.

The invention discloses a bone joint repairing composition containing stem cell vesicles and application of the bone joint repairing composition, and relates to the technical field of bone joint repairing compositions.The bone joint repairing composition is prepared from, by weight, 90-110 parts of stem cell vesicles and 41-57 parts of thelenota ananas saponin Ananaside A. The stem cell vesicles and the thelenota ananas saponin Ananaside A are combined to form the bone joint repairing composition. The stem cell vesicles are extracellular vesicles derived from human amniotic mesenchymal stem cells. According to the bone joint repairing composition provided by the invention, the stem cell vesicles and the thelenota ananas saponin in a proper proportion are matched for use, so that the synergistic interaction between the stem cell vesicles and the thelenota ananas saponin is realized. Animal experiments show that the composition has a remarkable repairing effect on a rat model with bone and joint injuries, can effectively relieve bone and joint pain symptoms of rats, not only widens the application field of human amniotic mesenchymal stem cell-derived extracellular vesicles, but also provides a new clinical treatment means for bone and joint repairing.

The invention relates to application of VBIT-4 or pharmaceutically acceptable salt thereof in preparation of drugs for preventing or treating vitiligo and complications thereof. A large number of modern pharmacological scientific researches and in-vivo pharmacodynamic tests prove that VBIT-4 has a treatment effect on a leucoderma mouse model and inhibits synthesis of inflammatory factors and chemotactic factors in a leucoderma mouse skin lesion area. The mechanism of the invention is that VBIT-4 inhibits the expression of inflammatory factors and chemotactic factors in skin tissues so as to treat leucoderma, compared with the existing treatment means, VBIT-4 can promote the compound color of pigments in a skin lesion region on the back of a leucoderma mouse, has no obvious toxicity, and reduces the expression level of inflammatory factors (IL-1beta, IL-6 and IFN-alpha) and chemotactic factors (CXCL9 and CXCL10). In conclusion, the VBIT-4 is clear in action mechanism, remarkable in effect and free of obvious side effects, and has remarkable advantages and progress compared with existing drugs.

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

The invention discloses a mouse model for treating in-situ pulmonary nodules by using bacterial lysates as well as a construction method and application of the mouse model. The method comprises the following steps: constructing an in-situ pulmonary nodule KT mouse model, instilling adenovirus, randomly dividing the model into an in-situ pulmonary nodule control group and a treatment group, performing bacterial lysate administration on mice in the treatment group at the maximum treatment dosage of 35mg / kg / d, and administering the same dosage of PBS solution to the control group. According to the invention, the possibility of killing cancer cells and preventing precancerous lesion progression by promoting autoimmunity of mice through oral immunostimulation drugs is provided for the first time, namely, the curative effect and mechanism of new drugs are researched through a mouse model, so that the clinical indications of the drugs are widened, and the blank field of clinical pulmonary nodule drug treatment is supplemented.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a small molecule compound P7C3 in preparation of a pharmaceutical preparation for inhibiting hepatic fibrosis. According to the invention, a CCl4-induced hepatic fibrosis mouse model is used for verifying the treatment effect of P7C3 on hepatic fibrosis. Meanwhile, the influence of P7C3 on HSC activation and proliferation is verified, eIF4A1 is a direct target of P7C3 for inhibiting HSC activation, and P7C3 is a promising anti-hepatic fibrosis therapeutic drug and an effective eIF4A1 inhibitor.

The invention discloses application of amantadine in inhibition of ITGAV in preparation of medicines for treating dry age-related macular degeneration, and belongs to the technical field of biological medicines. At present, no report for researching the ITGAV gene in the dry AMD exists, the specific action mechanism is not clear, and amantadine adaptation diseases do not include the dry AMD; according to the application disclosed by the invention, the gene target ITGAV is screened from mutual hair generation of microglial cells and RPE cells in a retina microenvironment, and amantadine is used for inhibiting ITGAV protein to relieve the progress of AMD, so that a new thought is provided for treating dry AMD. Experiments show that amantadine can inhibit ITGAV and delay EMT transformation of RPE cells. In a dry AMD mouse model induced by sodium iodate, RPE cell damage can be remarkably relieved by intraocular injection of amantadine, and the structure and function of a retina layer are improved. These results indicate that it may function in early intervention of dry AMD.

The invention relates to the technical field of gene engineering, in particular to a kit for constructing a TBX19 p.Thr187Ala point mutation mouse model as well as a construction method and application of the kit. The kit provided by the invention comprises gRNA (guide ribonucleic acid) of which the nucleotide sequence is shown as SEQ ID NO.1 and single-stranded Oligo donor DNA (deoxyribonucleic acid) of which the nucleotide sequence is shown as SEQ ID NO.3. The invention also provides a kit for detecting the gRNA. According to the kit provided by the invention, a TBX19 p.Thr187Ala point mutation mouse model can be constructed, and the mouse model can be used as an animal model for studying the occurrence and development course of a hypothalamus-pituitary-adrenal axis function weakening and acrenocorticotropin (ACTH) deficiency model, so as to study the molecular and cellular mechanism of the TBX19 gene influencing animal (mouse) behaviors. The animal model can also be used as an animal model for research and development of adrenocorticotropin deficiency drugs.

The invention discloses an application of lactobacillus mucosa LMSJ001 or a metabolite agmatine of the lactobacillus mucosa LMSJ001 in preparation of a medicine for improving intestinal aging, and the application research of the lactobacillus mucosa LMSJ001 in a constructed aging mouse model finds that the lactobacillus mucosa LMSJ001 can be used for preparing a medicine for improving intestinal aging. Therapeutic gavage and application of Lactobacillus mucosa LMSJ001 in colon organs for intervention can significantly improve aging indexes, alleviate histological aging performance, promote intestinal peristalsis of aged mice, reduce secretion of inflammatory factors of the aged mice, improve intestinal epithelial barrier functions of the aged mice and improve intestinal dryness of the aged mice. The lactobacillus mucosa LMSJ001 can generate a metabolite agmatine through arginine decarboxylase, and agmatine can improve related indexes of proliferation and differentiation of intestinal stem cells and reduce expression of related indexes of senescence. Based on the unique functions, the lactobacillus mucosa LMSJ001 or the metabolite agmatine of the lactobacillus mucosa LMSJ001 can be cooperated or complemented with other means, is used for preparing pharmaceutical compositions or detection kits and the like, and has very wide application prospects.

The invention discloses a construction method and application of a child inflammatory bowel disease rat model. The construction method comprises the following specific steps: smearing a 3% w / v oxazolone pre-sensitizing solution on the skin of a rat for pre-sensitization, and continuously performing repeated intermittent enema with a 1% w / v oxazolone enema. The model accords with the clinical manifestation and pathological characteristics of the children inflammatory bowel disease, and is a better model for researching the children inflammatory bowel disease.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention belongs to the technical field of biological medicine, and particularly relates to application of corynebacterium casei in preparation of medicine for preventing and treating lung injury. By constructing a radon inhalation-induced lung injury mouse model, after exposure at different radon levels, the weight of a mouse is reduced, the lung coefficient is increased, the tidal volume of the lung, the ventilation volume per minute and the maximum inspiration flow are reduced, the respiratory function is inhibited, the alveolar cavity of the mouse is abnormally expanded, the pulmonary septum is thickened and fractured, and more fibrin exudation is accompanied; the traditional Chinese medicine composition can be used for effectively inhibiting pulmonary fibrosis and lung injury due to obvious inflammatory infiltration beside bronchial tubes, extravasated blood in small blood vessels and lung tissue collagen deposition, and can be used for gavage of corynebacterium casei to effectively inhibit the above phenomena. Therefore, the corynebacterium casei can be used for preventing and treating lung injury, especially lung injury caused by radon exposure.

The invention discloses an establishment method and application of a damp-heat intestine accumulation type ulcerative colitis animal model, and belongs to the field of animal models.The establishment method comprises the steps that S1, high-fat feed treatment is conducted, specifically, experimental animals freely eat high-fat feed for 6-10 weeks from the first day; s2, DSS treatment: feeding 1.5% (w / v) DSS solution to the experimental animal for 2 weeks; and S3, observing the damp-heat syndrome type and ulcerative colitis related indications of the experimental animals, and selecting the experimental animals meeting the scoring standard, thereby establishing the ulcerative colitis mouse model. Aiming at the situation that most patients induce ulcerative colitis due to excess energy due to the change of dietary structures and lifestyles at present, the invention constructs and evaluates the damp-heat accumulation type ulcerative colitis mouse model by inducing internal dampness by a direct pathogenesis (high fat diet), which is closer to the actual situation of clinical patients. Therefore, a model and reference are provided for research and treatment of pathology of the damp-heat accumulation type ulcerative colitis and pharmacological mechanisms of traditional Chinese medicines.

The invention provides a construction method and application of a gene Idh1 conditional knockout mouse model and a preeclampsia heart injury animal model, and relates to the technical field of biology. According to the preeclampsia heart injury animal model, flox mice with conditional gene Idh1 knockout and mice with placental trophoblast specific expression Cre recombinase comate, PE-related phenotypes and typical symptoms of heart injury spontaneously appear in the double-positive pregnant mouse model, and the double-positive pregnant mouse model can be used for research of disease causes, diagnosis methods and drug research and development.

The application discloses a method for constructing a mouse model of atherosclerosis induced without high-fat diet, and relates to the technical field of disease model construction.The mouse model construction method provided by the application obtains a mouse model that spontaneously exhibits atherosclerosis symptoms without high-fat diet induction.The mouse model of atherosclerosis induced without high-fat diet can be used for researching the pathogenesis of atherosclerosis and screening and evaluating drugs for atherosclerosis.

The invention belongs to the field of biological genetic engineering, and particularly relates to a method for constructing a congenital heart disease mouse model. The invention provides gRNA (guide Ribonucleic Acid) for targeting a mouse Tmed1 gene. Nucleotide sequences of the gRNA are as shown in SEQ ID NO: 1 and SEQ ID NO: 2. Meanwhile, the invention provides a method for knocking out the mouse Tmed1 gene based on a CRISPR / Cas9 technology to obtain the mouse with the congenital heart disease. The Tmed1 mouse model is successfully constructed, a reliable mouse model is provided for congenital heart disease and visceral ectopic syndrome patients, subsequent detection and verification of upstream and downstream target gene functions and subsequent verification of development of related target drugs are facilitated, and great convenience is brought to disease mechanism research and drug research and development verification work.

The invention discloses a method for constructing a polycystic ovarian syndrome (PCOS) rat model with reduced sex hormone binding globulin (SHBG) on the basis of ruminococcus aureus with the preservation number of ATCC29149, and belongs to the technical field of animal models. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the dosage is 0.2-1 mL / 100 g, the intragastric administration frequency is one time per day to two times per week, and the time lasts for 4-8 weeks, such that the SHBG synthesis of the rat liver is induced to decrease, and the PCOS pathological characteristics such as testosterone level increase, estrus cycle disorder, ovarian polycystic change, insulin resistance and the like are initiated; the problem that a traditional hormone induction method does not conform to the physiological status is solved, the modeling period of a high-fat diet induction method is shortened, and an efficient experimental tool is provided for PCOS mechanism research and drug development.

The invention relates to a construction method and application of a periodontitis rat model, and the construction method comprises the following steps: firstly, performing toxoplasma gondii infection on rats, then performing porphyromonas gingivalis and treponema denticola co-infection on the toxoplasma gondii infected rats, and establishing the periodontitis rat model. The periodontitis animal model is rapidly and stably obtained through the synergistic effect of the porphyromonas gingivalis, the treponema denticola and the toxoplasma gondii, and the constructed periodontitis model is highly consistent with the symptoms and signs of human periodontitis, can reflect the systematicness and severity of periodontitis, and has a good application prospect. And the method has the advantages of high modeling speed, high success rate and good repeatability, and is convenient for researching infection, development mechanism and prevention and treatment process of periodontitis.

The invention belongs to the technical field of animal model construction, and particularly relates to a spontaneous pancreatic cancer mouse model and a construction method and application thereof. According to the construction method of the spontaneous pancreatic cancer mouse model, the two characteristics of MYC gene overexpression and PTEN gene knockout are applied to the same mouse individual at the same time, the mouse model capable of spontaneously and rapidly forming pancreatic cancer is constructed, the lifetime is short, and the development of related researches of pancreatic cancer is accelerated.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to tubeimoside B liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving phospholipid, cholesterol and PEGylated phospholipid in an organic solvent to form a mixed solution, and then evaporating the mixed solution to form a film; and hydrating the film by using an aqueous solution of tubeimoside B to finally prepare the tubeimoside B liposome. Compared with free tubeimoside B, the lipidosome has the advantages that the hemolysis percentage is obviously reduced, and antigen-specific humoral immune response and / or cellular immune response can be effectively enhanced when the lipidosome is used as a vaccine adjuvant. In an H1N1 influenza mouse model, the lipidosome combined antigen shows an excellent protection effect, which is shown in that the mouse weight fluctuation is relatively small and the lung virus load is remarkably reduced. The invention provides important theoretical basis and practical examples for developing low-toxicity and high-efficiency plant-derived vaccine adjuvants, and has a wide application prospect.

The invention relates to an N-acetyl-D-glucosamine composition with an anti-tumor effect and application of the N-acetyl-D-glucosamine composition, and relates to the technical field of medicines and health care products, the N-acetyl-D-glucosamine composition with the anti-tumor effect comprises the following raw materials by weight: 17-29 parts of N-acetyl-D-glucosamine and 5-10 parts of an extract of Tongshan. According to the invention, the N-acetyl-D-glucosamine and the extract in a proper proportion are matched for use for the first time, so that the synergistic interaction of the N-acetyl-D-glucosamine and the extract is realized. In-vitro animal anti-tumor experiments show that the N-acetyl-D-glucosamine composition provided by the invention can significantly reduce the tumor volume in a rat model, provides a new way for clinical treatment of tumor patients, and has a wide application prospect.

The invention discloses a construction method and application of a Keman ataxia rat model, and belongs to the technical field of animal models. The construction method of the Keman ataxia rat model comprises the step of mutating the 38th nucleotide of the ATCAY gene exon 3 of a rat from G to A. The constructed Kemann ataxia rat model provides a research mode tool for researching the function of the ATCAY gene in Kemann ataxia and screening or preparing medicines for preventing or treating Kemann ataxia.

The invention discloses a construction method and application of a Prpf6 gene mutation induced single dose insufficient RP mouse model, and belongs to the technical field of molecular biology and biomedicine. The mouse model constructed by using the method provides a convenient, reliable and economic means for researching the relationship between PRPF6 gene mutation and retinitis pigmentosa diseases and the pathogenesis of the PRPF6 gene mutation, and provides an effective research model capable of stably inheriting in the research on the aspects of RP pathogenesis, treatment methods, drug screening and the like. The animal model is subjected to transcriptome and a series of phenotype detection, wherein a transcriptome result shows that Prpf6 gene knockout mouse retina has occurred a certain degree of metabolic abnormality, electrophysiological detection, fundus examination and Hamp; e staining results show that the shapes and functions of the retinal cell layer and the retina of the mouse are damaged, and the disease phenotype of RP is met.

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The invention relates to the field of bioengineering, in particular to a bilateral cleft lip mouse model based on Pitx2-Cre conditional knockout of Bmp4 as well as a construction method and application of the bilateral cleft lip mouse model. The invention aims to construct a stable bilateral cleft lip mouse model. Experiments find that the Bmp4 gene is expressed in the epithelium of the frontal nose process and the maxillary process at the early lip stage in E9.25. The spatio-temporal expression mode of the Pitx2 gene in the early primordium epithelium is highly consistent with the spatio-temporal expression mode of the Bmp4 gene. Based on this, the inventor constructs a Bmp4 gene knockout model driven by an endogenous Pitx2 gene promoter, and finds that the mouse model shows a 100% bilateral cleft lip phenotype. Compared with the reported Netin-Cre, the Nestin-Cre has the advantages that the Nestin The bilateral cleft lip model constructed by the method is more stable, can better represent genetic diseases of human cleft lip, and has important research significance.